Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScCRISPR screens of CD8⁺ T cells in young vs. aged tumors and tdLNs

ABSTRACT: Single-cell in vivo CRISPR screens of CD8⁺ T cells across young and aged tumors and tumor-draining lymph nodes (tdLNs)

ORGANISM(S): Mus musculus

PROVIDER: GSE306058 | GEO | 2026/07/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

scCRISPR screens of CD8⁺ T cells in young vs. aged tumors and tdLNs

Project description:scCRISPR screens of CD8⁺ T cells in young vs. aged tumors and tdLNs

| PRJNA1309035 | ENA

Transcriptomes of premetastatic tumor-draining lymph nodes with or without denervation of TDLN-innervating nociceptive nerves

Project description:We compared the mice tumor-draining lymph nodes(TDLNs) with or without orthotopic tongue xenografts, and with or without denervation of TDLN-innervating nociceptive nerves

2026-02-20 | GSE225630 | GEO

RNA seq of tumor draining lymph node (TdLNs) from a wildtype (WT) or tenascin-C (TNC) knockout (KO) mouse each bearing 4NQO-carcinogen induced tongue tumors

Project description:Tumor-draining lymph nodes (TdLNs) were collected from wild-type (WT) and tenascin-C knockout (TNC-KO) C57BL/6 mice (N = 3 per group), each bearing 4NQO-induced tongue tumors. Both male and female mice were included. Beginning at 12 weeks of age, mice were exposed to 4NQO via drinking water for 16 weeks. Tumors were then subjected to a single 2 Gy irradiation. TdLNs were harvested six weeks after irradiation, and total RNA was isolated for bulk RNA-seq analysis.

2025-12-11 | E-MTAB-16360 | biostudies-arrayexpress

Spatio-temporal mapping of immune cell dynamics during human sequential lymph node metastasis

Project description:Regional lymph node metastasis critically influences distant metastatic progression, anti-tumour immunity, and patient prognosis. This study systematically characterised immune cell dynamics across paired primary tumours, sentinel tumour-draining lymph nodes (S-TDLNs), and secondary axillary lymph nodes (ALNs) from treatment-naïve triple-negative breast cancer (TNBC) patients using integrated multi-omics approaches, including imaging mass cytometry, single-cell RNA sequencing, Visium and Xenium spatial transcriptomics, and multiplex immunofluorescence. Xenium profiling was performed on FFPE lymph node sections spanning different metastatic stages to resolve high-resolution spatial organisation, neighbourhood complexity, and immune cell co-localisation during sequential lymph node metastasis.

2026-06-27 | GSE328422 | GEO

Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients

Project description:Tumor-draining lymph node (TDLN) invasion by metastatic cells in breast cancer correlates with poor prognosis and is associated with local immunosuppression, which can be partly mediated by regulatory T cells (Tregs). Here, we study Tregs from matched tumor-invaded and non-invaded TDLNs, and breast tumors. We observe that Treg frequencies increase with nodal invasion, that Tregs express higher levels of co-inhibitory/stimulatory receptors than effector cells. Also, while Tregs show conserved suppressive function in TDLN and tumor, conventional T cells (Tconvs) in TDLNs proliferate and produce Th1-inflammatory cytokines, but are dysfunctional in the tumor. We describe a common transcriptomic signature shared by Tregs from tumors and nodes, including CD80, which is significantly associated with poor patient survival. TCR RNA-sequencing analysis indicates trafficking between TDLNs and tumors and ongoing Tconv/Treg conversion. Overall, TDLN Tregs are functional and express a distinct pattern of druggable co-receptors, highlighting their potential as targets for cancer immunotherapy.

2020-05-26 | E-MTAB-9112 | biostudies-arrayexpress

CD8+MTs+ Effector T Cells from Enlarged Tumor-Draining Lymph Nodes Drive Enhanced Tumor Immunogenicity and Improved Prognosis in Colorectal Cancer Patients

Project description:Tumor-draining lymph nodes (TDLNs) play a crucial role in anti-tumor immunity. However, the heterogeneity of TDLNs significantly impacts their immune function. We employed single-cell RNA sequencing to dissect the immune landscape of TDLNs of colorectal cancer (CRC), revealing that enlarged non-metastatic TDLNs (L-TDLNs) are enriched with CD8+ effector T cells (Teff) exhibiting a distinct metallothionein (MT)-positive signature. These CD8+MTs+ Teff cells, characterized by heightened cytotoxicity and a stress-adapted phenotype, are critical mediators of anti-tumor immunity. Our data indicate that these cells migrate from L-TDLNs to tumor sites, enhancing tumor immunogenicity. Moreover, CRC patients with a high level of CD8+MTs+ Teff in tumor site showed a significant survival advantage, particularly when treated with adjuvant chemotherapy. These findings underscore the importance of L-TDLNs in shaping effective antitumor immune responses in CRC, suggesting that the CD8+MTs+ Teff cell population may serve as a novel prognostic biomarker and therapeutic target. Our study provides a comprehensive framework for understanding the cellular dynamics within TDLNs and their impact on CRC progression and treatment response.

2024-11-26 | GSE282542 | GEO

Single-cell RNA sequencing of CD45+ immune cells across primary tumor, sentinel tumor-draining lymph node, and axillary lymph node in treatment-naive triple-negative breast cancer

Project description:Regional lymph node metastasis critically influences distant metastatic progression, anti-tumor immunity, and patient prognosis in triple-negative breast cancer (TNBC). In this study, fresh surgically resected specimens from treatment-naive TNBC patients were collected and CD45+ immune cells were isolated for single-cell RNA sequencing to characterize immune remodeling across matched primary tumors, sentinel tumor-draining lymph nodes (S-TDLNs), and secondary axillary lymph nodes (ALNs). The overall project integrated scRNA-seq with imaging mass cytometry, Visium and Xenium spatial transcriptomics, and multiplex immunofluorescence. This GEO submission contains processed scRNA-seq expression matrices and associated metadata only. Raw sequencing data have been deposited previously in in the Genome Sequence Archive (GSA) for human data, and the GSA ID is HRA010347.

2026-06-27 | GSE328275 | GEO

PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity

Project description:Current cancer immunotherapies can induce tumour regression, although responses are often not durable. Recent studies have highlighted the importance of enforcing a systemic immune response from tumour-draining lymph nodes (TDLNs). However, mechanisms driving immune suppression in TDLNs remain poorly studied. We applied spatial proteogenomics on melanoma TDLNs and identified regional differences in immune cell composition in lymph nodes from patients with long-term (>5 years) disease control compared to those with early (<2 years) disease recurrence. TDLNs from patients with a poor prognosis were characterized by the expansion of regulatory T cells (Tregs), dendritic cells (DCs), and macrophages interacting with cytotoxic CD8+ T cells. Targeted transcriptomics of cell types within this spatial neighbourhood revealed immunoregulatory myeloid cell phenotypes engaging with CD8+ T cells poised for exhaustion. Besides known immune-suppressive molecules such as IDO and PD-L1, paracortex macrophages and DCs in patients with recurrent disease expressed high levels of the secreted phospholipase PLA2G2D across different cancer types. Additionally, PLA2G2D was upregulated in non-small cell lung cancer patients who developed acquired resistance to anti-PD-1 immunotherapy. Importantly, PLA2G2D loss-of-function or therapeutic inhibition markedly improved survival in tumour-bearing mice and increased the efficacy of anti-PD-1 immunotherapy. Collectively, we show that in-depth spatial profiling of cancer patient TDLNs offers novel insights into systemic anti-tumour immunity and identifies PLA2G2D as a target for cancer immunotherapy.

2026-06-23 | GSE333464 | GEO

Gene expression profiling of mature dendritic cells from mice s. c. treated with GM-CSF-gene transduced LLC cells (LLC/SeV/GM) or control cells (LLC, LLC/SeV/GFP)

Project description:Irradiated granulocyte macrophage-colony stimulating factor (GM-CSF)-transduced autologous tumor cells induce substantial antitumor immunity through the maturation and migration of dendritic cells (DCs). However, little is known about the key molecules involved in GM-CSF-sensitized DCs (GM-DCs) in tumor draining lymph nodes (TDLNs). We initially confirmed that mice subcutaneously injected with poorly immunogenic syngeneic Lewis lung carcinoma (LLC) cells transduced with Sendai virus encoding GM-CSF (LLC/SeV/GM) significantly rejected the tumor growth. Using microarray expression profiling, we obtained a large number of gene expression data files from GM-DCs and control DCs in TDLNs, and subjected them to network-based cluster analysis and unexpectedly unraveled the expression levels of type I IFNs-related genes specifically expressed in plasmacytoid DCs (pDC) were robustly up-regulated in GM-DCs. In vivo depletion assay showed that pDC-depleted mice treated with subcutaneous LLC/SeV/GM cells abrogated the antitumor effects observed in control mice. Moreover combination use of imiquimod for TLR7 triggering on pDC with irradiated LLC/SeV/GM cells induced a significant therapeutic antitumor effect with marked induction of CD9+ pDC with antitumor phenotype, whereas other control mice groups had only minimal to-modest antitumor responses, implicating that this combined vaccine strategy using imiquimod could be promising for improvement of GM-CSF-induced antitumor immunity. Mouse GM-CSF induced gene expression in mature dendritic cells in tumor draining lymph nodes from C57/BL6N female mouse was measured at 2 days after s.c. tumor challenge with GM-CSF gene-transduced LLC cells (LLC/SeV/GM) or control cells (LLC, LLC/SeV/GFP).

2013-09-30 | E-GEOD-43169 | biostudies-arrayexpress

Immune activated B cells are dominant in Prostate cancer - BCR sequencing

Project description:B cell receptor (BCR)-sequencing from 3 donors with prostate cancer. The sources are Peripheral blood B cells (P), tumour draining lymph nodes (S) and non-draining lymph nodes (N).

2023-01-01 | E-MTAB-11862 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data